Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vildagliptin + glinides
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vildagliptin + glinides is a combination therapy used for the treatment of type 2 diabetes mellitus. Vildagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that works by preventing the degradation of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, thereby increasing their concentration, promoting glucose-dependent insulin secretion, and suppressing inappropriate glucagon secretion[3]. Glinides are rapid-acting insulin secretagogues (such as repaglinide and nateglinide) that stimulate pancreatic beta cells to release insulin, primarily targeting postprandial blood glucose control by closing ATP-dependent potassium channels. The combination offers a complementary mechanism, with vildagliptin enhancing incretin action and glinides directly stimulating insulin release, resulting in better glycemic control without significant risk of hypoglycemia or weight gain.
- Brand names
- GalvusEucreas
- Other names
- dipeptidyl peptidase-4 inhibitor + glinidesDPP-4 inhibitor + glinides
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on vildagliptin + glinides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vildagliptin + glinides.